Investigating Exposure to Toxicants From Smoking and Vaping
NCT05953220 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160
Last updated 2023-07-20
Summary
Background:
Many people who smoke use vaping products to help them quit. Levels of toxicants in urine samples are substantially lower in those who exclusively vape compared to those who smoke, suggesting that vaping poses only a fraction of the harms as smoking. However, vaping is still not risk free, with some studies finding higher levels of some toxicants among vapers compared to those who do not smoke or vape. People with mental health conditions have different smoking patterns compared with the wider general population. It is not known if people with mental health conditions have different vaping pattens, therefore researchers do not know if they are exposed to different levels of vaping related toxicants. Also, smoking exposes people to high levels of polycyclic aromatic hydrocarbons (PAHs), which can reduce the effectiveness of some psychotropic medication and management of symptoms. Vaping exposes people to lower levels of PAHs than smoking, however it is unknown if the levels of PAHs from vaping affect the metabolization of psychotropic medicines.
The goal of this observational study is to learn about levels of tobacco toxicants among people with mental health conditions who vape, smoke, dual use or do neither.
The main question\[s\] it aims to answer are:
What are the levels of biomarkers of toxicant exposure among those who use community mental health services who exclusively vape, exclusively smoke, dual use or do neither, and how do they change over time? What is the difference in clozapine excretion levels and metabolism among those who use community mental health services who exclusively vape, exclusively smoke or dual use or do neither?
Participants will self report smoking and vaping characteristics and provide blood and urine samples at baseline and six months later. Urine will be analysed for tobacco toxicants. Blood will be analysed for levels of clozapine and other prescribed anti psychotic medication.
Researchers will compare levels of toxicants between people who vape, smoke, dual use, or do neither to see if these is a difference.
Conditions
- Smoking, Tobacco
- Vaping
- Mental Health Disorder
Interventions
- OTHER
-
Exclusive tobacco smoking
No intervention, participants own tobacco products
- OTHER
-
Exclusive e-cigarette use
No intervention, participants own e-cigarette products
- OTHER
-
Dual use of e-cigarettes and tobacco smoking
No intervention, participants own tobacco and e-cigarette products
- OTHER
-
No use of e-cigarettes or tobacco smoking
No intervention
Sponsors & Collaborators
- lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-08-31
- Primary Completion
- 2024-08-31
- Completion
- 2025-01-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Electronic Cigarettes in Daily Dependent Smokers
NCT02108626 ·Status: COMPLETED ·Phase: PHASE4
-
Treating Smokers With Mental Illness
NCT03822416 ·Status: COMPLETED ·Phase: PHASE2
-
Low Nicotine Cigarettes Plus Electronic Cigarettes
NCT04058717 ·Status: COMPLETED ·Phase: NA
-
Trial of Novel, On-Demand Virtual Reality to Amplify Practice Efficacy (NO VAPE) Added to Cognitive Behavioral Therapy for Nicotine Vaping Cessation
NCT07223879 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC
NCT05881304 ·Status: COMPLETED ·Phase: NA
-
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
NCT02870218 ·Status: COMPLETED ·Phase: PHASE2
-
Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
NCT04092101 ·Status: COMPLETED ·Phase: PHASE2
-
E-cigarette Nicotine Study
NCT04709471 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2
NCT00136838 ·Status: COMPLETED ·Phase: NA
-
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
NCT01928758 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes
NCT02185898 ·Status: COMPLETED ·Phase: NA
-
Varenicline for Nicotine Vaping Cessation in Adolescents
NCT05367492 ·Status: COMPLETED ·Phase: PHASE4
-
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
NCT02590393 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
E-cigarettes, Nicotine Inhaler, and Blood Vessel Function
NCT03072628 ·Status: COMPLETED ·Phase: NA
-
Effects of Novel E-cigarette Constituents on Adults TCORS 3.0
NCT05932745 ·Status: RECRUITING ·Phase: NA
-
Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans
NCT00616746 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Acute Effects of Vaping Nicotine on Cognition in Young Adults
NCT04901208 ·Status: COMPLETED ·Phase: NA
-
Treating Smokeless Tobacco Use in Rural Veterans
NCT02994082 ·Status: UNKNOWN ·Phase: NA
-
Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
NCT04210180 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Smoking Relapse Prevention in Schizophrenia
NCT00320697 ·Status: COMPLETED ·Phase: PHASE4
-
Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
NCT04092387 ·Status: COMPLETED ·Phase: NA
-
The Use of tDCS for Vaping Reduction
NCT06885606 ·Status: RECRUITING ·Phase: NA
-
Methadone-Maintained Smokers Switching to E-Cigarettes
NCT05206435 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
E-cigarettes and Blood Vessel Function
NCT02740595 ·Status: COMPLETED ·Phase: NA
-
Effects of Electronic Cigarette Settings and Liquid Concentrations in Cigarette Smokers and Electronic Cigarette Users
NCT03710590 ·Status: COMPLETED ·Phase: NA